Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Life sciences company Signalife has established a division focused on developing, acquiring and testing therapies capable of treating cardiovascular disease at an earlier state and in a more effective manner.
Subscribe to our email newsletter
The company has divisionalized Signalcare for the time being, and will evaluate placing Signalcare into a wholly-owned subsidiary after developments and relationships have materialized or have become formalized.
Lowell Harmison, Signalife’s president and CEO, said: “Through the use of our suite of heart monitoring devices and technologies, we believe that it is time to assist in moving the treatment of cardiovascular disease to earlier, less invasive and more predictable methodologies.”